Abstract:Tumor-infiltrating lymphocytes (TILs) play a critical role in tumor immune surveillance and immune suppression. Understanding tumor infiltrating T cell subset density, location and PD-1/PD-L1 expression might provide insight for the prediction of tumor therapeutic response and clinical outcome. The purpose of this study was to evaluate the expression and localization of CD8, FoxP3, PD-1, and PD-L1 in primary tumor tissues and their effects on prognosis of stage IV M0 locally advanced nasopharyngeal carcinoma (NPC) patients. Sixty NPC patients with stage IV M0 locally advanced disease were treated with definitive chemoradiation. Tumor biopsies from primary lesion were analyzed for the expression and localization of CD8, FoxP3, PD-1, and PD-L1 by immunohistochemistry. Their associations with local disease control and survival of NPC were analyzed. The average follow-up time was 43 months (range from 14 to 61 months). High expression of CD8+, FoxP3+, PD-1+ and PD-L1+ was observed in 60, 86.7, 56.7, and 91.7% of patients, respectively. There was no correlation between clinicopathological features and the expression of these immune markers. High PD-1 expression was found to be associated with lower local disease control (5-year LRFS 23.2% vs 96.8%, p < 0.001) and unfavorable clinical outcome (5-year OS 47.4% vs 73.3%, p = 0.014). In multivariate analysis, PD-1 expression was also an adverse prognostic factor for 5-year OS (HR: 3.68, P = 0.023) and LRFS (HR: 16.89, 1.27–11.84, P = 0.007). Those with PD-1 distribution in both stroma and tumor region had the poorest prognosis. However, PD-1 expression has no significant correlation with 5-year RRFS (p = 0.980) and DMFS (p = 0.865). Patients with both PD-1 and PD-L1 high expression had significant poor local disease control (5-year LRFS 96.0% vs 43.0%, p < 0.001) and overall survival (5-year OS 80.8% vs 45.1%, p < 0.001) compared with the others. Other immune markers were not found having corrections with disease control and survival. PD-1 high expression, especially with PD-L1 co-expression, is associated with high local recurrence and unfavorable clinical outcome for stage IV M0 NPC patients, and might be a potential target for immunotherapy.

Treatment-Related Lymphopenia is Possibly a Marker of Good Prognosis in Nasopharyngeal Carcinoma: a Propensity-Score Matching Analysis

Persistent Lymphopenia after Chemotherapy And/or Radiotherapy Predicted Unfavorable Outcome in Breast Cancer Patients - a Retrospective Cohort Study

High Proportion of Circulating CD8 + CD28- Senescent T Cells is an Independent Predictor of Distant Metastasis in Nasopharyngeal Canrcinoma after Radiotherapy

Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA

A Single Center Retrospective Study Assessing the Prognostic Significance of Pre-Treatment Neutrophil/lymphocyte Ratio in Locally Advanced Nasopharyngeal Carcinoma

Pretreatment Platelet Count Improves the Prognostic Performance of the TNM Staging System and Aids in Planning Therapeutic Regimens for Nasopharyngeal Carcinoma: a Single-Institutional Study of 2,626 Patients.

Prognostic Value of Nutritional Markers in Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy: a Propensity Score Matching Study

CD8+ Tumor-Infiltrating Lymphocyte Abundance Is a Positive Prognostic Indicator in Nasopharyngeal Cancer

Prognostic Value of Lymph Node Necrosis at Different N Stages in Patients with Nasopharyngeal Carcinoma

Prognostic Value of Post-Radiotherapy Neutrophil-to-lymphocyte Ratio in Locally Advanced Nasopharyngeal Carcinoma

Pretreatment Platelet Count As a Predictor for Survival and Distant Metastasis in Nasopharyngeal Carcinoma Patients.

High Expression of NLR and SII in patients With Nasopharyngeal Carcinoma as Potential Prognostic Observations

Prognostic Value of Immune Score in Nasopharyngeal Carcinoma Using Digital Pathology

High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma

A novel model for predicting prognosis and response to immunotherapy in nasopharyngeal carcinoma patients

Prognostic Study of Inflammatory Markers in Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy

Combined pre-treatment and middle-treatment Epstein–Barr virus DNA load contributes to prognostication and treatment modification in nasopharyngeal carcinoma patients

Nomograms based on the lymphocyte–albumin–neutrophil ratio (LANR) for predicting the prognosis of nasopharyngeal carcinoma patients after definitive radiotherapy

Prognostic Significance of the Novel Nutrition-Inflammation Marker of Lymphocyte-C-Reactive Protein Ratio in Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy

PD-1 High Expression Predicts Lower Local Disease Control in Stage IV M0 Nasopharyngeal Carcinoma

Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma